Neck dissection in the combined‐modality therapy of patients with locoregionally advanced head and neck cancer
- 10 March 2004
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 26 (5) , 447-455
- https://doi.org/10.1002/hed.10394
Abstract
Purpose. The purpose of this study was to evaluate the role of neck lymph node (ND) in the combined dissection modality therapy for locoregionally advanced head and neck. Methods. We identified patients with N2–N3 head and neck cancers who were enrolled in three consecutive multicenter phase II studies of concurrent chemoradiotherapy utilizing 5-fluorouracil and hydroxyurea on an alternate-week schedule with radiotherapy twice daily plus either cisplatin (C-FHX) or paclitaxel (T-FHX). Patients with unknown primary tumors, nasopharyngeal or paranasal sinus primaries, nonsquamous histology, progression or death during therapy, or incomplete therapy were excluded. Results. A total of 131 patients were analyzed. Seventy-nine percent had N2 stage. ND was performed in 92 patients (70%), either prior to enrollment (n = 31) or after chemoradiotherapy (n = 61). With a median follow-up of 4.6 years, the 5-year locoregional and neck progression-free survival (PFS) rates were higher in patients with ND versus patients without ND: 88% versus 74% (p = .02) and 99% versus 82% (p = .0007). respectively; there was also a trend toward improved overall survival (OS) with ND, but PFS and distant PFS were comparable. In the subset of patients with N3 disease, ND was associated not only with better locoregional control but also with improved distant PFS. However, in patients with clinical complete response (n = 92), no significant differences in PFS (68% vs 75% at 5 years, p = .53) or any other survival parameters with or without ND were observed. Conclusions. ND improves neck control and is required for patients with clinically residual disease or N3 neck cancer but has no significant impact on the outcome of patients with N2 stage disease who are rendered clinically disease-free with intensive concurrent chemoradiotherapy.© 2003 Wiley Periodicals, Inc. Head Neck 26: 447–455, 2004Keywords
This publication has 19 references indexed in Scilit:
- Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of FailureThe Oncologist, 2003
- Organ Preservation Therapy Using Induction Plus Concurrent Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania Phase II TrialJournal of Clinical Oncology, 2002
- Planned neck dissection after definitive radiotherapy for squamous cell carcinoma of the head and neckHead & Neck, 2002
- The Role of Neck Dissection After Chemoradiotherapy for Oropharyngeal Cancer With Advanced Nodal DiseaseJAMA Otolaryngology–Head & Neck Surgery, 2001
- The Role of Cervical Lymphadenectomy After Aggressive Concomitant ChemoradiotherapyJAMA Otolaryngology–Head & Neck Surgery, 2000
- Management Implications of Evaluating the N2 and N3 Neck After Organ Preservation TherapyThe Laryngoscope, 1999
- The management of the clinically positive neck as part of a larynx preservation approachInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trialInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservationThe Laryngoscope, 1992
- Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: Long-term follow-up of RTOG study 73-03International Journal of Radiation Oncology*Biology*Physics, 1991